Monoclonal Antibody- Drug Conjugation
Developing drugs that are ready to target disease and spare healthy tissue has beena long‐time goal of both oncologic and non‐oncologic drug development. Sincethe late nineteenth century, it's been recognized that effective treatment of disease by therapeutic agents is improved when therapeutics demonstrate selectiveness for foreign bodies (bacteria) or diseased cells and spare healthy cells. The development of novel and highly selective Antibody–Drug Conjugates (ADCs) has moved us closer to the present goal in cancer therapy. Agents such as Trastuzumab Emtansine (T‐DM1) and brentuximab vetoing have shown promising results, particularly in patients with advanced disease.